Vivoryon Therapeutics NV

AEX:VVY

Data takeaway: Varoglutamstat showed consistent, meaningful eGFR benefit across patients — including those with more impaired kidney function — supporting a Phase IIb in Stage IIIb/IV diabetic kidney disease (DKD).

Effect size: In the pooled Phase II program management cites a ~3.2 mL/year difference (active vs placebo); in the most affected DKD subgroups the active arm improved ~3–4 mL while placebo worsened, producing an ~7 mL gap in the worst patients.

Positioning: Management argues the profile is unique vs current standards (SGLT2/GLP-1), describing varoglutamstat as best-in-class because it stabilizes and can partially reverse eGFR over up to 2 years of treatment.

Financing: Completed an October private placement raising EUR 5.1 million; cash at end-September was EUR 2.5 million and management expects runway into Q3 2026 after the placement.

Spend reduction: YTD R&D and G&A costs fell versus prior year — R&D down to EUR 3.7M from EUR 12.6M and G&A to EUR 4.0M from EUR 4.9M — driving a narrower net loss.

Next steps: Company has selected a CRO, finalized a synopsis and is preparing Phase IIb; additional data analyses and preclinical work for orphan and other immune-mediated indications are ongoing.

Intellectual property: Oral QPCT/L inhibitor platform with patent protection extending at least until 2044.